FDA Approves Exelixis' Cabometyx To Treat Metastatic Differentiated Thyroid Cancer
18/9 06:11
(RTTNews) - The U.S. Food and Drug Administration approved Exelixis Inc.'s (EXEL) Cabometyx or cabozantinib for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following...